Palvella Therapeutics, Inc. (PVLA) — 10-K Filings
All 10-K filings from Palvella Therapeutics, Inc.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Palvella Reports Positive Phase 3 Data, Expands Pipeline Post-Merger
— Mar 31, 2026 Risk: high
Palvella Therapeutics, Inc. (PVLA) completed a merger on December 13, 2024, with Legacy Palvella, shifting its focus to developing novel therapies for rare skin -
Palvella Therapeutics Files 2024 10-K
— Mar 31, 2025 Risk: medium
Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024 -
Pieris Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K
— Mar 29, 2024 Risk: medium
PIERIS PHARMACEUTICALS, INC. (PVLA) filed a Annual Report (10-K) with the SEC on March 29, 2024. Pieris Pharmaceuticals, Inc. reported total assets of $98,935,0
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX